Oct. 21, 2025 -- Revium Rx (formerly Revium Recovery Inc. (OTC: RVRC), a biopharmaceutical company developing advanced lipid-based therapeutics for infectious and oncologic diseases, today announced significant progress in its regulatory and manufacturing programs supporting the planned Phase 1 clinical trial of its lead product candidate, Nano-Mupirocin - a novel systemic formulation of the well-known and highly potent antibiotic mupirocin. “Our novel formulation of Nano-Mupirocin is designed

– Next-generation siRNA therapeutic candidate with the potential for twice-yearly dosing – Oct. 22, 2025 -- ADARx Pharmaceuticals, Inc. (ADARx), a late-stage clinical biotechnology company developing next-generation RNA therapeutics, today announced that the first patient has been dosed in its Phase 3 STOP-HAE clinical trial evaluating ADX-324 in patients with hereditary angioedema (HAE). Additionally, ADARx announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Des

~ Late-breaking Phase 2 trial data evaluating the safety and efficacy of 25 mg of lorundrostat in participants with hypertension and comorbid CKD to be presented~ ~ Phase 3 data of the Launch-HTN Trial of lorundrostat to be included in “Best of Journal of the American Medical Association and the New England Journal of Medicine” presentation~ Oct. 21, 2025 -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hyper

Oct. 21, 2025 -- Simcha Therapeutics (“Simcha”), a clinical-stage immunobiology company pioneering first-in-class cytokine treatments for cancer, today announced the presentation of preclinical results which demonstrate enhanced efficacy from combining decoy-resistant IL-18 (DR-18), ST-067, with bispecific T-cell engagers (BiTEs) in multiple solid and hematologic cancer models. The presentation, titled “Decoy-resistant IL-18 combination with bispecific T-cell engager enhances anti-tumor efficac

Oct. 19, 2025 -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced data from a new ad hoc analysis from the IGNYTE phase 2 cohort of RP1 plus nivolumab was presented by Caroline Robert, M.D., Ph.D., at the European Society for Medical Oncology (ESMO) Congress 2025 being held in Berlin (Poster 1644P) The analysis of acral melanoma patients from the IGNYTE clinical trial showed treatment wit

IND opening marks culmination of partnership between Dewpoint and Evotec, advancing a de novo development candidate through IND-enabling studies First patient dosing planned before year-end 2025 at leading cancer centers in collaboration with top key opinion leaders Program validates Dewpoint’s condensate-modulator discovery platform and the value of agile, integrated partnerships in accelerating novel drug development. Oct. 21, 2025 -- Dewpoint Therapeutics today announced the opening of an I

Palazestrant in combination with ribociclib demonstrated encouraging activity across all dose cohorts and subgroups Median PFS was 15.5 months in the 120 mg palazestrant cohort across all patients In the 120 mg palazestrant cohort among patients with prior CDK4/6i treatment, median PFS was 9.2 months in patients with ESR1 wild-type tumors and 13.8 months in patients with ESR1 mutant tumors Combination continues to demonstrate favorable tolerability and a safety profile consistent with the known

Novel mechanism of action reverses and prevents death of injured cells Phase II ARPEGGIO trial fully enrolled Topline results to be presented at the World Stroke Congress, October 23, 2025 Oct. 17, 2025 -- Silver Creek Pharmaceuticals, Inc. (Silver Creek), a clinical-stage biotechnology company developing growth factor-based therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to scp776, its investigational therapy for acute ischemic

TNX-801 is a live virus vaccine investigational candidate, designed to provide durable protection against mpox and smallpox TNX-801 demonstrated favorable safety, immunogenicity, and long-term protection in multiple preclinical models Data support advancement of TNX-801 toward clinical development Oct. 17, 2025 -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”) presented data in an oral presentation at the World Vaccine Congress–Europe 2025, held October 14–16, 20

Data from the Phase Ib Beamion LUNG-1 trial evaluating zongertinib in treatment-naïve patients with advanced HER2 (ERBB2)-mutant NSCLC were presented for the first time at ESMO 2025. Confirmed response by blinded independent central review was 77%, with 96% of patients achieving disease control.1 Zongertinib recently received Breakthrough Therapy Designations for first-line treatment by the U.S. FDA and China’s CDE. Boehringer Ingelheim reported positive results from the Beamion LUNG-1 trial ev